DYRK1A and diabetes mellitus: In a recent study, a series of 1,5-naphthyridine derivatives for the chemical inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) have been described, as a promising therapeutic strategy for diabetes [21].